ReviewCurrent treatment options in neurology2019
Approaches to Remyelination Therapies in Multiple Sclerosis.
Review in Current treatment options in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Synthetic MRI in Progressive MS: Associations with Disability.AJNR. American journal of neuroradiology · 2025Article
- Oligodendrocyte and Myelin Pathophysiology in Multiple Sclerosis.Advances in neurobiology · 2025Review
- Trametinib, an anti-tumor drug, promotes oligodendrocytes generation and myelin formation.Acta pharmacologica Sinica · 2024Article
- p38γ MAPK delays myelination and remyelination and is abundant in multiple sclerosis lesions.Brain : a journal of neurology · 2024Article
- Visual outcome measures in clinical trials of remyelinating drugs.BMJ neurology open · 2024Review
- Efficacy of a benzothiazole-based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis.CNS neuroscience & therapeutics · 2024Article
- Pro-myelinating clemastine administration improves recording performance of chronically implanted microelectrodes and nearby neuronal health.Biomaterials · 2023Article
- Stable isotope labeling-mass spectrometry as a new approach to determine remyelination.Neural regeneration research · 2023Article
- Neuronal activity and remyelination: new insights into the molecular mechanisms and therapeutic advancements.Frontiers in cell and developmental biology · 2023Review
- Menstrual blood-derived mesenchymal stromal cells efficiently ameliorate experimental autoimmune encephalomyelitis by inhibiting T cell activation in mice.Stem cell research & therapy · 2022Article
- Clemastine Promotes Differentiation of Oligodendrocyte Progenitor Cells Through the Activation of ERK1/2Frontiers in pharmacology · 2022Article
- Bone marrow mesenchymal stem cells promote remyelination in spinal cord by driving oligodendrocyte progenitor cell differentiation via TNFα/RelB-Hes1 pathway: a rat model study of 2,5-hexanedione-induced neurotoxicity.Stem cell research & therapy · 2021Article
- Review
- Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation.International journal of molecular sciences · 2020Review
- Anacardic acid induces IL-33 and promotes remyelination in CNS.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- iPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu.PloS one · 2020Article
- Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs.BioResearch open access · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWhile there are a growing number of therapies targeting relapse prevention in multiple sclerosis (MS), there are no approved therapies promoting remyelination. Understanding endogenous myelin formation, remyelination strategies, pre-clinical models, and clinical outcomes is essential to the interpretation of current and future clinical trials of remyelinating agents. RECENT
findingsSeveral recent clinical trials of remyelination therapies, including opicinumab, clemastine, and GSK239512, showed negative or modest results. These results could highlight challenges translating pre-clinical studies into subjects with MS and current strategies to measure remyelination. Current approaches to remyelination include (1) blocking inhibitors of remyelination, (2) improving the clearance of myelin debris, (3) increasing the number of oligodendrocyte precursor cells (OPCs), and (4) stimulating OPC differentiation. To date, no therapies have led to robust remyelination. Future efforts to promote remyelination will likely require a combination of these mechanistic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.